Lipocine LPCN 1154 Phase 3 data accepted for oral presentation at 2026 ASCP meeting

Lipocine Inc.

Phase 3 data for LPCN 1154 (oral brexanolone) for postpartum depression accepted for oral and poster presentation at ASCP Annual Meeting May 26-29, 2026 in Miami, FL.
Oral presentation by Benjamin Bruno, PhD, VP Clinical Development, on May 26, 2026 at 3:20 PM ET; poster session on May 27.
LPCN 1154 is an oral non-SSRI neuroactive steroid that acts as a positive allosteric modulator of GABAA receptors.
Potential for acute stabilization of PPD symptoms with low CNS depressant side effects, no intensive monitoring required.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.